期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 126, 期 2, 页码 605-610出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI84428
关键词
-
资金
- National Institute of Allergy and Infectious Diseases (NIAID), NIH [5U19AI109946]
- Leukemia and Lymphoma Society of America
In vivo protection by antimicrobial neutralizing Abs can require the contribution of effector functions mediated by Fe-Fc gamma receptor (Fc-Fc gamma R) interactions for optimal efficacy. In influenza, broadly neutralizing anti-hemagglutinin (anti-HA) stalk mAbs require Fc-Fc gamma R interactions to mediate in vivo protection, but strain-specific anti-HA head mAbs do not. Whether this rule applies only to anti-stalk Abs or is applicable to any broadly neutralizing Ab (bNAb) against influenza is unknown. Here, we characterized the contribution of Fc-Fc gamma R interactions during in vivo protection for a panel of 13 anti-HA mAbs, including bNAbs and non-neutralizing Abs, against both the stalk and head domains. All classes of broadly binding anti-HA mAbs required Fc-Fc gamma R interactions to provide protection in vivo, including those mAbs that bind the HA head and those that do not neutralize virus in vitro. Further, abroadly neutralizing anti-neuraminidase (anti-NA) mAb also required Fc gamma Rs to provide protection in vivo, but a strain-specific anti-NA mAb did not. Thus, these findings suggest that the breadth of reactivity of anti-influenza Abs, regardless of their epitope, necessitates interactions with Fc gamma Rs on effector cell populations to mediate in vivo protection. These findings will guide the design of antiviral Ab therapeutics and inform vaccine design to elicit Abs with optimal binding properties and effector functions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据